Pfizer’s Business Units Enable It To Be Nimble Even as It Grows
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth integration is on track, with closing expected end of Q3 or Q4; anti-trust review is in early stages, with concern primarily about animal health overlap.